Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax in Colorectal Cancer
The randomised, open-label Phase II study, entitled “TaCTiCC” (TroVax® and Cyclophosphamide Treatment in Colorectal Cancer), builds on four previous Phase I/II trials conducted by Oxford BioMedica where TroVax® was given to patients with CRC, in addition to research into CRC undertaken by Dr Andrew Godkin and Dr Awen Gallimore at Cardiff University, Wales. Led by Dr Andrew Godkin, the study will enrol up to 54 patients with inoperable metastatic CRC. The study will evaluate whether TroVax®, administered alone or in combination with cyclophosphamide, is effective in the treatment of CRC. The study will assess anti-5T4 immune responses following treatment, in addition to secondary measures of clinical benefit including progression-free survival, objective response rate and overall survival.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.